Liquidia (NASDAQ:LQDA) Director Sells $548,000.00 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Arthur Kirsch sold 10,000 shares of Liquidia stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $54.80, for a total transaction of $548,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Liquidia Price Performance

NASDAQ LQDA opened at $61.85 on Friday. The firm’s fifty day simple moving average is $46.78 and its two-hundred day simple moving average is $39.56. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a 12-month low of $11.85 and a 12-month high of $66.24. The firm has a market capitalization of $5.50 billion, a P/E ratio of 441.82 and a beta of 0.58.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia’s quarterly revenue was up 4187.1% compared to the same quarter last year. Analysts forecast that Liquidia Corporation will post 2.97 EPS for the current fiscal year.

Institutional Investors Weigh In On Liquidia

A number of large investors have recently made changes to their positions in the stock. Farallon Capital Management LLC grew its holdings in shares of Liquidia by 1.1% during the fourth quarter. Farallon Capital Management LLC now owns 8,656,038 shares of the company’s stock valued at $298,547,000 after buying an additional 90,400 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Liquidia by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company’s stock valued at $138,439,000 after buying an additional 52,671 shares during the last quarter. Opaleye Management Inc. boosted its holdings in Liquidia by 9.5% in the second quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock valued at $30,838,000 after purchasing an additional 215,000 shares during the last quarter. Bank of America Corp DE boosted its holdings in Liquidia by 18.7% in the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after purchasing an additional 360,372 shares during the last quarter. Finally, Caprock Group LLC boosted its holdings in Liquidia by 9.3% in the fourth quarter. Caprock Group LLC now owns 1,783,921 shares of the company’s stock valued at $61,527,000 after purchasing an additional 151,832 shares during the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on LQDA. Lifesci Capital raised shares of Liquidia to a “strong-buy” rating in a report on Thursday, March 5th. Wall Street Zen raised shares of Liquidia from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 16th. Needham & Company LLC lifted their price target on shares of Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Oppenheimer set a $75.00 price target on shares of Liquidia in a report on Friday. Finally, Wells Fargo & Company boosted their price objective on shares of Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Three research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $55.63.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).